Comparative Pharmacology
Head-to-head clinical analysis: ISOPTO CETAPRED versus OCUSULF 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPTO CETAPRED versus OCUSULF 10.
ISOPTO CETAPRED vs OCUSULF-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of sulfonamide antibiotic (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene production.
Sulfacetamide sodium is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and exerting bacteriostatic effects.
1-2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be administered every 1-2 hours until response then gradually taper.
Instill 1 drop into the affected eye(s) every 4 hours while awake.
None Documented
None Documented
Sulfacetamide: 7-13 hours (prolonged in renal impairment); Prednisolone: 2.5-3.5 hours (independent of dose). Total duration of anti-inflammatory effect exceeds half-life due to genomic effects.
1.5–2.5 hours (terminal) in adults; prolonged to 3–5 hours in renal impairment (CrCl <30 mL/min).
Renal: sulfacetamide is excreted unchanged in urine (30-40%); prednisolone is metabolized and excreted renally (10-20%) and fecally (30-40%) as conjugates.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic